Breast Cancer Clinical Trial
Study Evaluating HKI-272 in Tumors
Summary
The purpose of this study is to evaluate the safety and tolerability as well as find the maximum tolerated dose (MTD) for HKI-272. In addition, this study will examine the effects of the study drug on your tumor, and how your body uses and eliminates HKI-272.
Eligibility Criteria
Inclusion Criteria:
Her2/neu or Her1/EGFR positive cancer
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
Exclusion Criteria:
Prior treatment with anthracyclines with a cumulative dose of doxorubicin or equivalent of greater than 300 mg/m^2
Patients with significant cardiac risk factors
Active central nervous system metastasis
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Tampa Florida, 33612, United States
Boston Massachusetts, 02115, United States
Saint Louis Missouri, 63110, United States
Cleveland Ohio, 44195, United States
Nashville Tennessee, 37203, United States
How clear is this clinincal trial information?
![Survivornet Logo](https://assets.survivornet.com/wp-content/uploads/2024/07/10151222/survivornet-logo-blue.png)
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.